Skip to main content

. 1987 Feb 28;294(6571):546–547. doi: 10.1136/bmj.294.6571.546

Rapid progression of a growth hormone producing tumour during dopamine agonist treatment.

K Heidvall, A L Hulting

PMCID: PMC1245581 PMID: 3103768

546

Images in this article

p546-a
on p.546

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Lamberts S. W., Liuzzi A., Chiodini P. G., Verde S., Klijn J. G., Birkenhäger J. C. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest. 1982 Apr;12(2):151–155. doi: 10.1111/j.1365-2362.1982.tb00952.x. [DOI] [PubMed] [Google Scholar]
Pelkonen R., Ylikahri R., Karonen S. L. Bomocriptine treatment of patients with acromegaly resistant to conventional therapy. Clin Endocrinol (Oxf) 1980 Mar;12(3):219–224. doi: 10.1111/j.1365-2265.1980.tb02703.x. [DOI] [PubMed] [Google Scholar]
Sarkar D. K., Gottschall P. E., Meites J. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology. 1984 Oct;115(4):1269–1274. doi: 10.1210/endo-115-4-1269. [DOI] [PubMed] [Google Scholar]
Wass J. A., Thorner M. O., Morris D. V., Rees L. H., Mason A. S., Jones A. E., Besser G. M. Long-term treatment of acromegaly with bromocriptine. Br Med J. 1977 Apr 2;1(6065):875–878. doi: 10.1136/bmj.1.6065.875. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES